Edwards Lifesciences Corp (EW), a known entity in the bio-tech market, have had mixed performances in comparison to their colleagues. Despite consecutive winnings, as well as losses, it possessed a strong trading day and showcased robust Q4 and Fiscal Year 2023 metrics. Alphabetically. Edwards Lifesciences applications achieved a decisive regulatory triumph with both their EVOQUE Valve Replacement System earning FDA endorsement and their acquisition of Innovalve observed as a crucial step toward fortifying their TMVR solutions. EW has gained several institutional shareholders and has proven to be an attractive investment, providing 42% returns in the last five years. This company is also looking to sell its critical care product group to Becton Dickinson (BDX) for $4.2 billion while also planning a critical care unit spin-off in 2024. Becoming a focussed heart-oriented company, EW exhibited growth strategies during their Annual Investor Conference, despite public sales of shares by Edward Lifesciences executives and partners, such as Wealthspire Advisors LLC.
Edwards Lifesciences Corp EW News Analytics from Tue, 29 Aug 2023 07:00:00 GMT to Sun, 21 Jul 2024 18:55:28 GMT -
Rating -2
- Innovation 6
- Information 7
- Rumor 0
